Invizius logo

Invizius

Healthcare & Life Sciences

Recent Finacing

Equity

Recent Raise

$1.3M


Invizius is a biotech company developing H-Guard, a product designed to reduce inflammatory responses in dialysis and ICU patients undergoing continuous renal replacement therapy.

Total Funding

$13M

Headquarters

Edinburgh, United Kingdom

Founded

2018

Focus Areas

biotech
clinical trials
inflammatory response
dialysis
renal replacement therapy
acute kidney injury

Investors

Mercia Ventures logo
Scottish Enterprise logo
Calculus Capital logo
University of Edinburgh logo
Syensqo logo